Is Avelumab available in China?

Avelumab (Avelumab) is an emerging cancer treatment drug. The original drug has not yet been launched in China. The specific launch time is not yet clear, but there is hope that it will be launched in China. Avelumab is well tolerated as a single agent or in combination, has a safety profile similar to other anti-PD-1/PD-L1 agents, and can be used to treat metastatic Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. Based on pharmacokinetics, target occupancy and immunological analysis of dose-escalation trials in solid tumors, avelumab at 10 mg/kg intravenously every 2 weeks was selected as its recommended dose.